drugset / Trial / NCT07759362

Study to Assess KN3835 in the Treatment of Flexible/Semi-Flexible Hammertoe (HMT)

NCT07759362 ↗

Phase 3 Recruiting 554 enrolled Endo USA Inc., a Keenova Therapeutics Company
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The primary purpose of this study is to assess the efficacy, safety, and tolerability of KN3835 compared to placebo in the treatment of flexible/semi-flexible HMT.

Timeline

Start
2026-08-11
Primary completion
2027-12
Completion
2027-12

Drugs

EvaluationDrugModalityDoseRoute
Subject KN3835 Unknown — —

Indications